181 related articles for article (PubMed ID: 11049017)
1. Arsenicals in hematologic cancers.
Novick SC; Warrell RP
Semin Oncol; 2000 Oct; 27(5):495-501. PubMed ID: 11049017
[TBL] [Abstract][Full Text] [Related]
2. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
Douer D; Tallman MS
J Clin Oncol; 2005 Apr; 23(10):2396-410. PubMed ID: 15800332
[TBL] [Abstract][Full Text] [Related]
3. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
Verstovsek S; Giles F; Quintás-Cardama A; Perez N; Ravandi-Kashani F; Beran M; Freireich E; Kantarjian H
Hematol Oncol; 2006 Dec; 24(4):181-8. PubMed ID: 16783836
[TBL] [Abstract][Full Text] [Related]
4. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
Amadori S; Fenaux P; Ludwig H; O'dwyer M; Sanz M
Curr Med Res Opin; 2005 Mar; 21(3):403-11. PubMed ID: 15811209
[TBL] [Abstract][Full Text] [Related]
5. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
Barbey JT; Pezzullo JC; Soignet SL
J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391
[TBL] [Abstract][Full Text] [Related]
6. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience.
Lazo G; Kantarjian H; Estey E; Thomas D; O'Brien S; Cortes J
Cancer; 2003 May; 97(9):2218-24. PubMed ID: 12712474
[TBL] [Abstract][Full Text] [Related]
7. Arsenic trioxide as effective therapy for relapsed acute promyelocytic leukemia.
Mayorga J; Richardson-Hardin C; Dicke KA
Clin J Oncol Nurs; 2002; 6(6):341-6. PubMed ID: 12434466
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring.
Ohnishi K; Yoshida H; Shigeno K; Nakamura S; Fujisawa S; Naito K; Shinjo K; Fujita Y; Matsui H; Sahara N; Takeshita A; Satoh H; Terada H; Ohno R
Leukemia; 2002 Apr; 16(4):617-22. PubMed ID: 11960341
[TBL] [Abstract][Full Text] [Related]
9. [Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
Lengfelder E; Schultheis B; Büchner T; Hehlmann R
Dtsch Med Wochenschr; 2007 Feb; 132(7):330-6. PubMed ID: 17286223
[No Abstract] [Full Text] [Related]
10. The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia.
Zhang P
J Biol Regul Homeost Agents; 1999; 13(4):195-200. PubMed ID: 10703942
[TBL] [Abstract][Full Text] [Related]
11. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia.
Lengfelder E; Hofmann WK; Nowak D
Leukemia; 2012 Mar; 26(3):433-42. PubMed ID: 21904379
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide: safety issues and their management.
Au WY; Kwong YL
Acta Pharmacol Sin; 2008 Mar; 29(3):296-304. PubMed ID: 18298894
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide: new preparation. Acute promyelocytic leukaemia: encouraging results but persistent doubts.
Prescrire Int; 2004 Aug; 13(72):135-7. PubMed ID: 15532137
[TBL] [Abstract][Full Text] [Related]
14. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
Knipp S; Gattermann N; Schapira M; Käferstein H; Germing U
Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide and acute promyelocytic leukemia: clinical and biological.
Chen Z; Zhao WL; Shen ZX; Li JM; Chen SJ; Zhu J; Lallemand-Breittenbach V; Zhou J; Guillemin MC; Vitoux D; de Thé H
Curr Top Microbiol Immunol; 2007; 313():129-44. PubMed ID: 17217042
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia.
Zhang Y; Zhang Z; Li J; Li L; Han X; Han L; Hu L; Wang S; Zhao Y; Li X; Zhang Y; Fan S; Lv C; Li Y; Su Y; Zhao H; Zhang X; Zhou J
Cancer; 2013 Jan; 119(1):115-25. PubMed ID: 22930197
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence.
Sanz MA; Fenaux P; Lo Coco F;
Haematologica; 2005 Sep; 90(9):1231-5. PubMed ID: 16154847
[TBL] [Abstract][Full Text] [Related]
18. Comparing two arsenic trioxide administration methods in APL therapy.
Zhou J; Meng R; Yang BF
Chin Med J (Engl); 2004 Sep; 117(9):1411-3. PubMed ID: 15377438
[No Abstract] [Full Text] [Related]
19. Clinical activity of arsenic trioxide for the treatment of multiple myeloma.
Munshi NC; Tricot G; Desikan R; Badros A; Zangari M; Toor A; Morris C; Anaissie E; Barlogie B
Leukemia; 2002 Sep; 16(9):1835-7. PubMed ID: 12200700
[TBL] [Abstract][Full Text] [Related]
20. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.
Soignet SL; Maslak P; Wang ZG; Jhanwar S; Calleja E; Dardashti LJ; Corso D; DeBlasio A; Gabrilove J; Scheinberg DA; Pandolfi PP; Warrell RP
N Engl J Med; 1998 Nov; 339(19):1341-8. PubMed ID: 9801394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]